About PAN2-PAN3 deadenylation complex catalytic subunit PAN2
PAN2-PAN3 deadenylation complex catalytic subunit PAN2 (PAN2) is a protein
from Homo sapiens identified by UniProt accession
Q504Q3, 1202 residues long.
MolForge cross-references it against 0 known binders and
47 disease associations.
Target properties
| Protein name | PAN2-PAN3 deadenylation complex catalytic subunit PAN2 |
|---|
| UniProt accession | Q504Q3 |
|---|
| Gene | PAN2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1202 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (47)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.50
- Abnormality of the eye · score 0.37
- Abnormality of head or neck · score 0.37
- Intellectual disability · score 0.37
- Sensorineural hearing impairment · score 0.37
- disease of genitourinary system · score 0.37
- Seizure · score 0.37
- Global developmental delay · score 0.37
- Abnormality of the skeletal system · score 0.37
- Abnormality of the cardiovascular system · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q504Q3-F1 | alphafold | PREDICTED | 78.99 | — |
Amino-acid sequence (1202 residues)
MNFEGLDPGL AEYAPAMHSA LDPVLDAHLN PSLLQNVELD PEGVALEALP VQESVHIMEG VYSELHSVVA EVGVPVSVSH FDLHEEMLWV GSHGGHATSF FGPALERYSS FQVNGSDDIR QIQSLENGIL FLTKNNLKYM ARGGLIIFDY LLDENEDMHS LLLTDSSTLL VGGLQNHIIE IDLNTVQETQ KYAVETPGVT IMRQTNRFFF CGHTSGKVSL RDLRTFKVEH EFDAFSGSLS DFDVHGNLLA ACGFSSRLTG LACDRFLKVY DLRMMRAITP LQVHVDPAFL RFIPTYTSRL AIISQSGQCQ FCEPTGLANP ADIFHVNPVG PLLMTFDVSA SKQALAFGDS EGCVHLWTDS PEPSFNPYSR ETEFALPCLV DSLPPLDWSQ DLLPLSLIPV PLTTDTLLSD WPAANSAPAP RRAPPVDAEI LRTMKKVGFI GYAPNPRTRL RNQIPYRLKE SDSEFDSFSQ VTESPVGREE EPHLHMVSKK YRKVTIKYSK LGLEDFDFKH YNKTLFAGLE PHIPNAYCNC MIQVLYFLEP VRCLIQNHLC QKEFCLACEL GFLFHMLDLS RGDPCQGNNF LRAFRTIPEA SALGLILADS DEASGKGNLA RLIQRWNRFI LTQLHQDMQE LEIPQAYRGA GGSSFCSSGD SVIGQLFSCE MENCSLCRCG SETVRASSTL LFTLSYPDGS KSDKTGKNYD FAQVLKRSIC LDQNTQAWCD TCEKYQPTIQ TRNIRHLPDI LVINCEVNSS KEADFWRMQA EVAFKMAVKK HGGEISKNKE FALADWKELG SPEGVLVCPS IEELKNVWLP FSIRMKMTKN KGLDVCNWTD GDEMQWGPAR AEEEHGVYVY DLMATVVHIL DSRTGGSLVA HIKVGETYHQ RKEGVTHQQW YLFNDFLIEP IDKHEAVQFD MNWKVPAILY YVKRNLNSRY NLNIKNPIEA SVLLAEASLA RKQRKTHTTF IPLMLNEMPQ IGDLVGLDAE FVTLNEEEAE LRSDGTKSTI KPSQMSVARI TCVRGQGPNE GIPFIDDYIS TQEQVVDYLT QYSGIKPGDL DAKISSKHLT TLKSTYLKLR FLIDIGVKFV GHGLQKDFRV INLMVPKDQV LDTVYLFHMP RKRMISLRFL AWYFLDLKIQ GETHDSIEDA RTALQLYRKY LELSKNGTEP ESFHKVLKGL YEKGRKMDWK VPEPEGQTSP KNAAVFSSVL AL
Explore PAN2-PAN3 deadenylation complex catalytic subunit PAN2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets